<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112666">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958866</url>
  </required_header>
  <id_info>
    <org_study_id>0156</org_study_id>
    <nct_id>NCT01958866</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Tinospora Crispa-extract Product Compared With the Acetaminophen</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Tinospora Crispa-extract Product can reduce pyretic similar to acetaminophen.

      This study aims to investigate the efficacy and safety of Tinospora Crispa-extract product
      compared with the acetaminophen. Total of 96 patients with body temperature between
      37.8-38.5 without any signs of infections will be enrolled in this study. Patients will be
      randomly divided into 3 groups: First group will receive acetaminophen 1000 mg every 6 hr,
      Second group will receive Tinospora Crispa-extract Product 2000 mg twice daily and the third
      group will receive placebo twice daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in each group will be monitored for body temperature at baseline (at the time of
      enrollment) and at 1, 2, 4, 6, 8, 24 h after receiving the tested material.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Change from baseline in temperature at 1, 2, 3, 4, 6, 8, 12 and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events: diarrhea, elevated liver enzyme and elevated creatinine</measure>
    <time_frame>Participants will be followed for the duration of hospital stay (24 hours)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Liver and kidney function will be randomly evaluated. Number of participants with soft stool will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Patients With Body Temperature Between 37.8-38.5</condition>
  <condition>No Sign of Infection</condition>
  <condition>No Liver and Kidney Problem</condition>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tinospora Crispa-extract Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinospora Crispa-extract Product</intervention_name>
    <arm_group_label>Tinospora Crispa-extract Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <arm_group_label>Acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years old

          -  Body temperature between 37.8-38.5

          -  Body weight not less than 40 kg but not over 100 kg

          -  Liver enzymes do not exceed 2 times of normal value

          -  Can comply with study protocol

        Exclusion Criteria:

          -  Have allergic history of any tested compounds

          -  Fever from other causes, not by URI

          -  Take any herbal medicines during 2 weeks before enrollment

          -  Physicians decide to withdraw the subjects with any reasons
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pornanong Aramwit</last_name>
    <phone>+66899217255</phone>
    <email>aramwit@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pornanong Aramwit</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pornanong Aramwit, PharmD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pornanong Aramwit, PharmD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Pornanong Aramwit, Pharm.D., Ph.D</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fever</keyword>
  <keyword>Body temperature</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
